文献速递心脑血管急症复苏、休克与脓毒症

COVID-19大流行期间心血管急症的管理

Management of cardiovascular emergencies during the COVID-19 pandemic.
PubMed 文献 · Emerg Med J · 2020-10-13
一句话结论封锁期间心血管急症患者就诊延迟、再灌注治疗减少、ACS住院死亡率从2.69%升至7.27%。

该研究回顾了印度西部四家三级区域急诊科在政府实施完全封锁期间就诊的心血管急症患者。封锁期25.0%的患者在症状发作12小时后就诊,高于封锁前17.4%和COVID前6%。ST段抬高型心肌梗死患者接受急诊导管治疗的比例从COVID前46.9%降至封锁前26.1%和封锁期18.8%,而静脉溶栓治疗比例从COVID前18.4%升至封锁后32.3%。急性冠脉综合征住院死亡率从COVID前2.69%升至封锁后7.27%,非ACS急症如急性失代偿性心力衰竭和高度或完全性房室传导阻滞的急诊入院也显著下降。

要点

  • 封锁期25.0%的心血管急症患者在症状发作12小时后就诊,高于封锁前17.4%和COVID前6%。
  • ST段抬高型心肌梗死急诊导管治疗比例:COVID前46.9% vs 封锁前26.1% vs 封锁期18.8%。
  • 静脉溶栓治疗比例从COVID前18.4%升至封锁后32.3%。
  • 急性冠脉综合征住院死亡率从COVID前2.69%升至封锁后7.27%。
  • 非ACS急症(急性失代偿性心力衰竭、高度或完全性房室传导阻滞)急诊入院显著下降。

适用人群与场景

  • 就诊于印度西部四家三级区域急诊科的心血管急症患者,涵盖政府实施完全封锁期间、封锁前和COVID前三个时期。

研究设计与关键结果

  • 研究类型为回顾性研究,纳入四家三级区域急诊科的心血管急症患者。
  • 封锁期25.0%的患者和封锁前17.4%的患者在症状发作12小时后就诊,而COVID前仅6%。
  • ST段抬高型心肌梗死患者接受急诊导管治疗的比例:COVID前46.9%,封锁前26.1%,封锁期18.8%。
  • 静脉溶栓治疗比例从COVID前18.4%升至封锁后32.3%。
  • 急性冠脉综合征住院死亡率从COVID前2.69%升至封锁后7.27%。
  • 非ACS急症如急性失代偿性心力衰竭和高度或完全性房室传导阻滞的急诊入院显著下降。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • COVID-19大流行导致患者因心脏问题就医延迟,并影响了本机构最佳治疗的使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: It has been reported that patients attending the emergency department with other pathologies may not have received optimal medical care due to the lockdown measures in the early phase of the COVID-19 pandemic.

METHODS: This was a retrospective study of patients presenting with cardiovascular emergencies to four tertiary regional emergency departments in western India during the government implementation of complete lockdown.

RESULTS: 25.0% of patients during the lockdown period and 17.4% of patients during the pre-lockdown period presented outside the window period (presentation after 12 hours of symptom onset) compared with only 6% during the pre-COVID period. In the pre-COVID period, 46.9% of patients with ST elevation myocardial infarction underwent emergent catheterisation, while in the pre-lockdown and lockdown periods, these values were 26.1% and 18.8%, respectively. The proportion of patients treated with intravenous thrombolytic therapy increased from 18.4% in the pre-COVID period to 32.3% in the post-lockdown period. Inhospital mortality for acute coronary syndrome (ACS) increased from 2.69% in the pre-COVID period to 7.27% in the post-lockdown period. There was also a significant decline in emergency admissions for non-ACS conditions, such as acute decompensated heart failure and high degree or complete atrioventricular block.

CONCLUSION: The COVID-19 pandemic has led to delays in patients seeking care for cardiac problems and also affected the use of optimum therapy in our institutions.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Choudhary R, Gautam D, Mathur R, et al. Management of cardiovascular emergencies during the COVID-19 pandemic. Emerg Med J. 2020. PMID: 33051275. doi:10.1136/emermed-2020-210231

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。